number king jili
Apple is expected to launch a new iPhone 17 Air next year along with other models which is reportedly has entered the New Product Introduction (NPI) phase. What does it mean? Apple’s next big thing, the iPhone 17 Air, is reportedly moving closer to becoming a reality. According to industry insiders, the device has entered the New Product Introduction (NPI) phase at Foxconn, which means it’s on its way from concept to production. Rumour has it this could be Apple’s thinnest smartphone yet, possibly replacing the ‘Plus’ model in the 2025 iPhone lineup. For those who are unaware, the NPI phase is basically where Apple and its partners like Foxconn figure out how to make the phone on a large scale. During this phase, they perfect the concept, conduct prototype testing, and devise plans for the mass assembly of the iPhone. On the condition that such alterations do not adversely affect the way the phone is constructed. iPhone 17 Air: What To Expect? Design : According to leaks, the iPhone 17 Air is said to be one of if not the thinnest smartphone Apple has ever produced measuring around 6mm thickness which is a reduction of roughly 25% from its predecessor, the rumours suggested. It could incorporate a protruding camera which may be located in the rear center but most probably it will have only a single camera rather than two as is the case with most smartphones. Display and Sound: The screen size has a chance of being reminiscent of that of the iPhone 16 Plus although the body would be significantly thinner. In order to achieve an ultra-thin body, Apple may choose to eliminate the second speaker located at the bottom of the device and retain the single speaker that is activatable via the earpiece only. Battery Life: It may be a thin design but it also probably means that the battery has a small capacity although in spite of being small, we have already established there capacity has yet to be provided. Apple seems to be testing the waters with the iPhone 17 Air’s sleek design, possibly hinting at a future direction for all iPhones. Even with some compromises, its unique form factor could attract users looking for a stylish, ultra-thin device. As we look forward to more accurate information, it is an interesting thought to even think of what Apple could be working on! As the most valuable company in the world seems set to expand its catalogue, there are already whispers of OLED MacBooks and even a folding iPhone in the pipeline. At the moment, the iPhone 17 Air appears to be one of the most exciting products for Apple that the company has ever designed. Click for more latest Mobile Phone news . Also get top headlines and latest news from India and around the world at News9. Divya is a Senior Sub-Editor with about 3 years of experience in journalism and content writing. Before joining News9live, she had contributed to Times Now and Hindustan Times, where she focused on tech reporting and reviewing gadgets. When she's not working, you can find her indulging in Netflix, expressing her creativity through painting, and dancing.Gastrointestinal Cancer Drugs Market Size, Share, Trends, Opportunities, and Forecasts 2024 to 2031 | Amgen, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd 11-21-2024 09:44 PM CET | Health & Medicine Press release from: DataM Intelligence 4 Market Research LLP DataM Intelligence The latest report on Gastrointestinal Cancer Drugs Market offers valuable insights into emerging trends and pivotal developments within the market. It highlights significant growth opportunities that market participants can leverage, alongside strategic recommendations for capitalizing on these trends. This report serves as an indispensable tool for stakeholders seeking to deepen their understanding of the market landscape and identify actionable pathways for growth. By utilizing this in-depth analysis, stakeholders will gain the insights necessary to effectively adapt to shifting market conditions and strengthen their competitive position. Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/gastrointestinal-cancer-drugs-market Gastrointestinal Cancer Drugs Market is expected to grow at a CAGR of 5% during the forecast period (2024-2031). Key Developments: On 26th January 2018, the U.S. Food and Drug Administration approved Lutathera (lutetium Lu 177 dotatate) for the treatment of gastroenteropancreatic neuroendocrine tumors, a kind of cancer that affects the pancreas or gastrointestinal tract (GEP-NETs). The therapy of GEP-NETs using a radioactive medication, or radiopharmaceutical, has never been authorized before. Adult patients with GEP-NETs that are somatostatin receptor-positive are eligible for lutathera. List of the Key Players in the Gastrointestinal Cancer Drugs Market: Novartis AG, Amgen, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson Private Limited, GlaxoSmithKline plc., Celgene Corporation, Pfizer Inc and Sanofi. Research Process: Both primary and secondary data sources have been used in the global Gastrointestinal Cancer Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges. Segment Covered in the Gastrointestinal Cancer Drugs Market: By Therapy (Targeted Therapy, Chemotherapy, Radiation therapy, Surgery, Others) By End-users (Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Clinics, Others), Regional Outlook: The global Gastrointestinal Cancer Drugs Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa. Get Customization in the report as per your requirements+Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/gastrointestinal-cancer-drugs-market Regional Analysis: The global Gastrointestinal Cancer Drugs Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Gastrointestinal Cancer Drugs Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications. **The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted** Points Covered: ⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Gastrointestinal Cancer Drugs market segments, study objectives, and years considered. ⏩ Market Landscape: The competition in the Global Gastrointestinal Cancer Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies. ⏩ Companies Profiles: The global Gastrointestinal Cancer Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production. ⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study. ⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Gastrointestinal Cancer Drugs Market. ⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type. ⏩ Research Findings: This section of the report showcases the findings and analysis of the report. ⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided. Unlock Year-End Savings! Get Up to 30% Off: https://www.datamintelligence.com/buy-now-page?report=gastrointestinal-cancer-drugs-market Frequently Asked Questions ● What is the expected growth rate of the global Gastrointestinal Cancer Drugs market for the forecast period? ● What are the key driving factors that are responsible to shape the fate of the Gastrointestinal Cancer Drugs market during the forecast period? ● What will be the overall size of the market during the analysis period? ● What are the prominent market trends which influence the development of the Gastrointestinal Cancer Drugs market across various regions? ● Who are the key market players and the market strategies that have helped them to secure the leading position in the global Gastrointestinal Cancer Drugs market? ● What are the challenges and threats that are likely to act as a barrier to the growth of the Gastrointestinal Cancer Drugs market? ● What are the major opportunities that the companies can get to attain success in the world? Contact Us - Company Name: DataM Intelligence Contact Person: Sai Kiran Email: Sai.k@datamintelligence.com Phone: +1 877 441 4866 Website: https://www.datamintelligence.com About Us - DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele. This release was published on openPR.
Nine college football conference champions will be crowned by the end of the weekend. There are plenty of questions to be answered, including: Who will earn automatic byes in the College Football Playoff and who will be left out? But perhaps the biggest question of all is this: Are these games necessary? The allure of the conference championship weekend is a day and a half of football between some of the best teams. Most of the games, including the SEC title game between No. 2 Texas and No. 5 Georgia in Atlanta, will be played in front of packed houses at NFL stadiums. Most of the games have playoff implications. That sounds nice, but with this year's expanded, 12-team playoff, it's time to admit the truth: Conference championship games aren't needed. For example, take SMU (11-1), whom the CFP committee on Tuesday ranked three spots ahead of No. 11 Alabama (9-3). SMU's only loss is an 18-15 defeat Sept. 6 against BYU — a team that was highly ranked and looking at a first-round bye a few weeks ago. SMU has beaten a pair of ranked teams since then (No. 22 Louisville and No. 18 Pitt). Alabama has ridden a rollercoaster this season, beating ranked Georgia, Missouri and LSU but losing big at unranked Oklahoma as well as at unranked Vanderbilt and at Tennessee, then ranked seventh. Alabama will be watching games on television this weekend. On Saturday at Bank of America Stadium in Charlotte, N.C., SMU will play No. 17 Clemson (9-3) in the ACC Championship Game. CFP chair Warde Manuel said Tuesday that an SMU loss could be detrimental to its playoff hopes. "Potentially, yes. And they can move above teams, as well. Again, it just depends on the outcome of the game," he said when asked if SMU could drop below Alabama should it lose the ACC Championship game. Conference championships can help a team get into the playoffs or improve its seeding. But the fact that it could hurt a team if it loses makes an already muddy picture even more unclear. Why should SMU play Saturday? It's ranked eighth and with a loss, the Mustangs could fall out of the playoff while teams behind them sit at home. That stinks. No. 10 Boise State (11-1) could make a similar argument. The Broncos defeated No. 20 UNLV (10-2) on Oct. 25, but they must beat the Rebels again Friday night to cement their CFP bid. Meanwhile, No. 6 Ohio State (10-2), No. 7 Tennessee (10-2) and teams with outside CFP shots won't have to play this week and therefore potentially suffer the consequences of a loss. The solution is simple: There's no need for conference championships. Automatic byes should go to the regular-season champions of the Power Four conferences (ACC, Big Ten, Big 12, SEC). Teams can then be judged fairly across the standard 12 games. The committee's job is easier when all teams are on a level playing field in terms of games played. Instead, some schools could end up losing out because they had to take the field while others didn't. That's no way to make a championship game seem attractive.
Chiefs’ Nagy addresses Mahomes’ outburst last game, need to shore up offense
Trump 2.0 has a Cabinet and executive branch of different ideas and eclectic personalitiesAmateur internet sleuths are racing to identify the gunman who killed the chief of the nation’s largest health insurer in midtown Manhattan on Wednesday, hoping to piece together clues and beat police investigators at their own high-profile manhunt. The shooter seemingly vanished after being caught on video in one of the world’s most surveilled cities, offering an online community of wannabe detectives a tantalizing case. They pored over street footage and digital data to guess his brand of backpack , debate how he had silenced his pistol and scrutinize his getaway bike .Trudeau, Carney push back over Trump’s ongoing 51st state comments
At least one judge has seen the transphobic hysteria for what it is. In denying a request to upend this week’s Mountain West volleyball tournament and/or force San Jose State to leave one of its players home, a federal judge called out the disingenuousness of the lawsuit. And in doing so, revealed the farce behind this sudden groundswell of opposition to transgender women athletes. “The Court finds their delay in filing this action and seeking emergency relief related to the MWC Tournament weakens their arguments," U.S. District Judge S. Kato Crews wrote in his ruling issued Monday. “The movants could have sought injunctive relief much earlier if the exigencies of the circumstances required mandatory court intervention.” For three years now, San Jose State’s volleyball team has included a transgender woman. (Neither the young woman nor San Jose State has confirmed it but, as Crews pointed out, no one has denied it, either.) The Mountain West Conference created a participation policy for transgender athletes back in 2022, which included forfeit as punishment for refusing to play a team with a transgender athlete, and athletic directors at every school in the conference agreed to it. Yet not until this season, after the player had been outed by a right-wing website and then thrown under the bus by one of her own teammates, did the howling and forfeits begin. This is an important point, so I’m going to repeat it: For two years, the San Jose State player was on the volleyball team and the world continued to spin. No one was injured, no one was assaulted in a locker room, no legion of transgender women showed up in formation behind her to take over women’s sports. The San Jose State player practiced and played and no one, not her teammates and not her opponents, took issue with it. Whether that’s because no one realized she’s transgender or it was deemed inconsequential are two sides of the same coin. So what changed? Other than teammate Brooke Slusser and the other grifters deciding that demonizing a young woman would get them a spot on Fox News? Nothing . Not a damn thing. If the San Jose State player was such a threat, if the Mountain West’s transgender participation policy was so onerous, surely the athletes and the schools who filed the lawsuit would have done so immediately. Unless, of course, this was all for show. In which case, waiting until the 11 th hour would add fuel to their faux outrage. “At the earliest, Moving Plaintiffs or their institutions began to learn that one of SJSU’s teammates was an alleged trans woman with an article published in the spring of 2024. And they certainly had knowledge of this alleged player when the string of member institutions started forfeiting matches against SJSU in September 2024,” Crews wrote. Predictably, Slusser and three other athletes filed a notice of appeal. But the likelihood of it succeeding would seem to be slim, as well, given Crews’ painstaking detailing of precedent. The anti-trans ilk likes to claim that allowing transgender women to play sports is a violation of Title IX. But Crews says it’s actually the opposite, taking five pages of his 28-page ruling to cite previous Supreme Court and Tenth Circuit cases that found discriminating against someone for being transgender is sex discrimination. Which is prohibited by Title IX. “The (plaintiffs') Title IX theory raised in this case directly conflicts with Title IX’s prohibition on discrimination against trans individuals,” Crews wrote. San Jose State is the No. 2 seed in the Mountain West Conference tournament, which begins Wednesday. The Spartans have a bye in the first round and will play either Boise State or Utah State on Friday. Those are two of the schools that forfeited games during the regular season, which means we’re about to find out how committed to the bigotry those teams are. For all the shrieking there is about transgender women athletes, it’s the cisgender women pushing the forfeits who cost their fellow athletes opportunities to play and saddled their teams with losses. It’s those women, not the San Jose State player, who are the real threat . Follow USA TODAY Sports columnist Nancy Armour on social media @nrarmour.Marler to retire from rugby on Friday, a month after quitting international duty with England